Attached files
file | filename |
---|---|
EX-99.2 - EX-99.2 - Wave Life Sciences Ltd. | d495597dex992.htm |
EX-99.1 - EX-99.1 - Wave Life Sciences Ltd. | d495597dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): December 10, 2017
WAVE LIFE SCIENCES LTD.
(Exact name of registrant as specified in its charter)
Singapore | 001-37627 | Not Applicable | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) | ||
8 Cross Street #10-00, PWC Building Singapore 048424 |
048424 | |||
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code: +65 6236 3388
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 7.01 | Regulation FD Disclosure. |
On December 10, 2017, data from preclinical studies of WVE-3972-01, Wave Life Sciences Ltd.s (the Company) investigational stereopure antisense oligonucleotide designed to target the pathogenic allele of the C9ORF72 gene for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), were presented at the 28th International Symposium on ALS/MND. These data were presented by Robert Brown, Jr., DPhil, MD, with whom the Company is working in collaboration to further understand neurodegenerative and neuromuscular diseases, including ALS, and characterize the pharmacology of oligonucleotides. The slides presented containing these data are furnished as Exhibit 99.1 to this Current Report on Form 8-K.
In addition, on December 11, 2017, the Company issued a press release announcing these data. A copy of the press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K.
The information in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, is intended to be furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
The following exhibits relating to Item 7.01 of this Current Report on Form 8-K shall be deemed to be furnished and not filed:
Exhibit No. |
Description | |
99.1 | Slides presented on December 10, 2017 | |
99.2 | Press release issued on December 11, 2017 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
WAVE LIFE SCIENCES LTD. | ||||||
Date: December 11, 2017 | /s/ Keith C. Regnante | |||||
Keith C. Regnante | ||||||
Chief Financial Officer |